UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
December 23, 2003
-----------------
(Date of Report)
ELITE PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 333-45241 22-3542636
---------------------------- ------------ -------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
165 Ludlow Avenue, Northvale, New Jersey 07647
----------------------------------------------
(Address of principal executive offices)
(201) 750-2646
----------------------------------------------------
(Registrant's telephone number, including area code)
Item 5. Other Events and Regulation FD Disclosure
-----------------------------------------
Registrant issued on December 23, 2003 a press release announcing its
agreement with Pivotal Development, LLC to develop a controlled release product
utilizing Elite's proprietary drug delivery technology.
A copy of Registrant's press release is attached as Exhibit 99.1.
Item 7. Financial Statements and Exhibits
---------------------------------
a) Not applicable.
b) Not applicable.
c) Exhibits
99.1. Press Release, dated December 23, 2003
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: December 23, 2003
ELITE PHARMACEUTICALS, INC.
By: /s/ BERNARD BERK
------------------------------
Name: Bernard Berk
Title: Chief Executive Officer
3